Elopag 50 (Eltrombopag) 50 mg Tablets

Indicated for adult patients and, in some cases, pediatric patients as prescribed by a physician for the following conditions:

• 🔹 Chronic Immune Thrombocytopenia (ITP): in patients with insufficient response to corticosteroids, immunoglobulins, or splenectomy.
• 🔹 Thrombocytopenia associated with chronic hepatitis C: to enable initiation and continuation of antiviral therapy.
• 🔹 Severe Aplastic Anemia: in patients with inadequate response to immunosuppressive treatment.

Packaging: 50 mg tablets.

⚠️ ADMINISTRATION PROTOCOL:

• Starting Dose: Determined individually by the physician depending on diagnosis, platelet count, age, and ethnic considerations.
• Food Intake: Take on an empty stomach or with a meal low in calcium.
• Important: Do not take together with dairy products, antacids, or supplements containing calcium, magnesium, aluminum, iron, selenium, or zinc. A gap of at least 4 hours should be maintained.
• Monitoring: Regular monitoring of platelet count, liver function tests, and complete blood count is required.
• Note: Dose adjustments should only be made by the treating physician based on laboratory findings.

• Hypersensitivity to Eltrombopag or any component of the product.
• Use with caution in patients with hepatic impairment.
• High risk of thrombosis and thromboembolic complications.
• Pregnancy and breastfeeding — use only when clearly indicated by a physician.

Common and clinically important adverse reactions include:

• 🩸 Blood/Vascular: Increased risk of thrombosis and thromboembolism.
• 📉 Gastrointestinal: Nausea, diarrhea, abdominal pain, decreased appetite.
• 🧪 Liver: Increased ALT, AST, bilirubin, possible hepatotoxicity.
• 💢 General: Headache, weakness, fatigue.
• 👁 Other: Possible development or progression of cataracts with long-term use.